Journal of Clinical Oncology (JCO) Podcast

Latest Episodes:

Surviving Childhood Cancer: Defining Risk of Poor Cardiac Outcomes in Early and Middle Adulthood Apr 02, 2012

Show notes

This podcast provides observations and commentary on the JCO article "High risk of symptomatic cardiac events in childhood cancer survivors.

No Advantage to Combining Cetuximab with 5FU, Leucovorin, and Oxaliplatin in Metastatic Colorectal Cancer Apr 02, 2012

Show notes

This podcast reviews a negative phase III clinical trial of cetuximab combined with chemotherapy in first-line metastatic colorectal cancer and focuses on the interaction of targeted therapy combined with chemotherapy.

Sorting Through Early Melanomas to Identify Those at Higher Risk for Metastases Mar 12, 2012

Show notes

This podcast partitions patients with early melanoma into those with very favorable features and compares them to those with a higher risk for dying of metastatic melanoma.

Sedation for the Management of Refractory Suffering Mar 12, 2012

Show notes

Incorporating the information form Dr Marconi's systematic review on the question "Does sedation at the end of life hasten death", I will provide useful guidance regarding how to discuss this issues with patients and their families.

The Role of the Estrogen Receptor (ER) in Selecting Women, Diagnosed with DCIS for Adjuvant Therapy with Tamoxifen Mar 05, 2012

Show notes

This podcast describes the results from a subgroup of 732 women in the NSABP B-24 trial for the treatment of DCIS, where ER status was available, and describes how this can be used as a predictive test for response to adjuvant tamoxifen.

How Cooperative Group Trials Impact Breast Cancer Care in United States Mar 05, 2012

Show notes

In this podcast, I will review a JCO article showing that the publication of CALGB C9343 trial results had little influence in practice patterns in the United States. I will discuss possible study-specific reasons for the lack in change of practice and explore the author's implication that practitioners are more apt to adopt trials that add technologies and/or treatments compared to those that withhold therapies.

What's Different Between One Colorectal Cancer and Another? It's All in the Genes Mar 05, 2012

Show notes

This podcast will discuss the current role of characterizing KRAS and BRAF in the management of colorectal cancer as well as a manuscript by Popovici and colleagues entitled "Identification of a poor prognosis BRAF-mutant-like population of colon cancer patients". In this manuscript, a molecular signature that characterizes a subgroup of colorectal cancers that behave like BRAF mutant tumors but do not have true BRAF mutations. The research moves beyond analysis of a single gene to characterize a tumor's phenotype.

Molecular Tumor Analyses Followed by First Line Oral Tyrosine Kinase Inhibitors in Lung Adenocarcinomas with Driver Abnormalities Feb 28, 2012

Show notes

Patients with epidermal growth factor receptor (EGFR) gene mutations should receive EGFR tyrosine kinase inhibitors as 1st line therapy because they produce higher response rates, long progression free survival, reduced toxicity, improved symptom control and convenience of oral administration compared to chemotherapy doublets.

Placing the P Value into Perspective: Does Paclitaxel Add Value to Gemcitabine and Cisplatin in Advanced Urothelial Cancers? Feb 28, 2012

Show notes

This JCO Podcast provides observations and commentary on the JCO article, "Randomized Phase III study comparing Paclitaxel Cisplatin Gemcitabine and Gemcitabine Cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC 30987 Intergroup Study" by Joaquim Bellmunt et al. It provides my perspective that considers both statistical metrics and clinical outcomes in decision making for difficult to treat diseases.

Early Stage Hodgkin Lymphoma -- How Much is Enough? Feb 21, 2012

Show notes

The management of patients with early stage Hodgkin lymphoma with unfavorable characteristics remains a topic for study.